Cartesian Therapeutics Inc. Capital Reinvestment Ratio
Cartesian Therapeutics Inc. capital reinvestment ratio. Cartesian Therapeutics Inc. (RNAC) has a Capital Reinvestment Ratio of 0.45x as of September 2024, meaning it reinvests 0% of its operating cash flow ($13.69 Million) in capital expenditures ($6.20 Million). Check total reinvestment intensity of Cartesian Therapeutics Inc. to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Cartesian Therapeutics Inc. (2020–2020)
Capital reinvestment ratio of Cartesian Therapeutics Inc. from 2020 to 2020. This chart tracks Cartesian Therapeutics Inc.'s Capital Reinvestment Ratio across 1 annual periods. Also explore Cartesian Therapeutics Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Cartesian Therapeutics Inc. Capital Reinvestment Ratio by Year (2020–2020)
Cartesian Therapeutics Inc. capital reinvestment ratio by year from 2020 to 2020. For the full cash flow conversion analysis, see cash flow conversion of Cartesian Therapeutics Inc..
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.02x | $34.88 Million | $815.00K | — |